Bristol Myers Squibb (BMS) has partnered with Accenture to open Mosaic, a generative AI-enabled content hub in Mumbai designed to support the biopharmaceutical company’s global commercialization efforts.

Billed as a first-of-its-kind, end-to-end platform, Mosaic is built to strengthen BMS’s digital marketing capabilities by identifying physicians’ educational needs in real time and enabling the rapid creation of personalized, patient-centric content at scale. The hub brings together creative and technology teams to modernize how commercial content is developed and delivered across global markets.

“The future of healthcare is about meeting clinicians and patients where they are and doing so in meaningful ways. This partnership reflects our BMS approach to end-to-end digital transformation,” said Adam Lenkowsky, Chief Commercialization Officer at BMS.

The Mumbai hub forms part of BMS’s broader $130 million investment in artificial intelligence initiatives across its marketing operations. By leveraging India’s deep digital expertise and collaborative innovation ecosystem, the company aims to develop and scale next-generation AI-driven solutions for worldwide use.

Mosaic also builds on a 25-year relationship between BMS and Accenture that has evolved from traditional service delivery into a wide-ranging digital transformation partnership. Through the new hub, the two companies plan to reimagine biopharma marketing using advanced AI tools.

“Accenture and Bristol Myers Squibb are leading the AI-forward reinvention of biopharma by applying innovative technologies to generate meaningful outcomes for patients,” said Ndidi Oteh, CEO of Accenture Song.